Biogen hints at jobs cuts unless government pays up
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
Aduhelm verdict puts the heat on Biogen – and on the FDA
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
Reata rout leaves next project in doubt
Bardoxolone looks dead after yesterday’s adcom vote, but what about omaveloxolone?
Covid-19 tests versus Omicron
The new variant might be able to dodge one of the PCR tests authorised in the US, the FDA says.
